Background. We recently reported anti-CD40 monoclonal antibody and rapamycin (aCD40/rapa) to be a reliable, nontoxic, immunosuppressive regimen for combined islet and kidney transplantation (CIKTx) in nonhuman primates. In the current study, we attempted to induce allograft tolerance through the mixed chimerism approach using a conditioning regimen with aCD40 and belatacept (Bela). Methods. Five CIKTx or kidney transplant alone recipients were treated with aCD40/rapa for 4 months. All recipients then received a conditioning regimen including horse antithymocyte globulin and aCD40/Bela. The results were compared with previous reports of recipients treated with Bela-based regimens. Results. All 3 CIKTx recipients developed mixed chimerism, which was significantly superior to that observed in the previous Bela-based studies. Nevertheless, all CIKTx recipients in this study lost their islet and renal allografts as a result of cellular and humoral rejection on days 140, 89, and 84. The 2 kidney transplant-alone recipients were treated with the same conditioning regimen and suffered rejection on days 127 and 116, despite the development of excellent chimerism. B lymphocyte reconstitution dominated by memory phenotypes was associated with early development of donor-specific antibodies in 4 of 5 recipients. In vitro assays showed no donor-specific regulatory T cell expansion, which has been consistently observed in tolerant recipients with our mixed chimerism approach. Conclusions. Despite displaying excellent immunosuppressive efficacy, costimulatory blockade with anti-CD40 monoclonal antibody (2C10R4) may inhibit the induction of renal or islet allograft tolerance via a mixed chimerism approach.
W e previously developed a clinically applicable conditioning regimen for simultaneous kidney and bone marrow transplantation (SKBMT) in nonhuman primates (NHPs) using horse antithymocyte globulin (hATG) and belatacept (Bela/hATG) . 1 This protocol was subsequently modified for deceased donor transplantation by delaying donor bone marrow transplantation (DBMT) until 4 months after kidney transplantation (delayed DBMT). 2 In the delayed tolerance protocol, more profound T cell depletion with rabbit antithymocyte globulin (rATG) in place of hATG was required to suppress memory T cell (T MEM ) responses presumably induced by the renal allograft despite conventional immunosuppression administered until DBMT. However, when this delayed DBMT was applied to combined islet and kidney transplantation (CIKTx), a prominent inflammatory cytokine syndrome elicited by rATG 3 resulted in loss of islet function. Therefore, we further revised the delayed DBMT regimen for CIKTx recipients by restoring hATG, expecting only moderate T-cell depletion but less inflammatory responses. To suppress T MEM responses after DBMT, we instead added anti-CD40 monoclonal antibody (mAb), which has been demonstrated to have inhibitory effects on T MEM in NHP transplant models. 3, 4 Furthermore, the synergistic effect of anti-CD40 mAb and CTLA4Ig has been suggested in murine allograft models 5 and in an NHP bone marrow transplant model.
In the current study, we evaluated the efficacy of dual costimulatory blockade (CB) with anti-CD40 mAb and Bela for induction of allograft tolerance via the mixed chimerism approach.
MATERIALS AND METHODS

Animals and Pair Selections
A total of 10 cynomolgus monkeys, including donor animals, weighing 3 to 8 kg were used for this study (Charles River Primates, Wilmington, MA). Donors and recipients were paired based on ABO compatibility and major histocompatibility complex (MHC) mismatching. MHC characterization was performed as previously described. 7, 8 All surgical procedures as well as postoperative care of animals was performed in accordance with National Institutes of Health guidelines for the care and use of primates and approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee.
Experimental Design
The results from aCD40/Bela/hATG-treated animals were compared with results from previously reported recipients who received either Bela/hATG 1 or Bela/rATG.
2
Maintenance Immunosuppression Before DBMT Three cynomolgus monkeys received CIKTx and 2 received kidney transplant (KTx) alone from MHC-mismatched donors. All monkeys were treated with anti-CD40 mAb 9 (NIH Nonhuman Primate Reagent Resource, Boston, MA, Cat PR-4047, RRID:AB_2716325) (2C10R4: 20 mg/kg intravenously (i.v.) on days 0, 2, 5, 7, 9, and weekly at 10 mg/kg) plus daily rapamycin (LC laboratories, Woburn, MA) intramuscularly (i.m.) from day 0 to maintain trough levels at 10 to 15 ng/mL. Anti-inflammatory therapy, including tocilizumab (Chugai Pharm, Tokyo, Japan) (anti-IL-6R mAb: 10 mg/kg i.v. on days 0 and 5) and etanercept (Immunex, Seattle, WA) (TNF-alpha receptor fusion protein: 25 mg i.v. on days 0, 3, 7, and 10), was administered to all recipients ( Figure 1A ). 3 Conditioning Regimen for DBMT Used in This Study aCD40/Bela/hATG (n = 5): Four months after CIKTx or KTx alone, all NHP recipients were conditioned with total body irradiation (TBI) (1.5 Gy on days −6 and −5, relative to the day of DBMT), local thymic irradiation (TI: 7 Gy on day −1), and hATG (Atgam; Pharmacia and Upjohn, Kalamazoo, MI: 50 mg/kg i.v. on days −2, −1, and 0). After DBMT, the recipients were treated with anti-CD40 mAb (2C10R4: 20 mg/kg i.v. on days 0 and 2, 5, 7, 9, and 12 post-DBMT) and Bela (provided by Bristol Meyer Squibb, New York, NY: 20 mg/kg i.v. on days 0, 2, 5, and 15 post-DBMT). Cyclosporine A (CyA) (Novartis, Basel, Switzerland) was administered i. m. on days 1 to 28 post-DBMT, after which no immunosuppression was administered ( Figure 1A ).
Conditioning Regiments From Previous Studies
Bela/hATG (n = 5) 1 : The conditioning regimen consisted of low-dose TBI (1.5 Gy Â 2) on days −6 and −5 relative to simultaneous kidney and bone marrow transplantation (SKBMT), TI on day −1, hATG (50 mg/kg Â 3 on days −2, −1, and 0, relative to SKBMT), and Bela (20 mg/kg Â 4 on days 0, 2, 5, and 15, relative to SKBMT). A 1-month course of CyA was administered to maintain therapeutic trough levels of 250 to 350 ng/mL ( Figure 1B ). 1 Bela/rATG (n = 4) 2 : all recipients initially underwent KTx alone with a conventional triple drug immunosuppressive regimen consisting of tacrolimus (Astellas Pharma, Inc., Osaka, Japan) (starting with 0.1 mg/kg per day i.m. to maintain trough levels of 10-20 ng/dL), mycophenolate mofetil FIGURE 1. The DBMT conditioning regimens with or without anti-CD40 mAb. aCD40/Bela/hATG: 2 to 3 weeks before CIKTx, cynomolgus monkey recipients received STZ (75 mg/kg) for induction of diabetes. After transplantation, the CIKTx or KTx-alone recipients received the same immunosuppressive therapy with anti-CD40 mAb and rapamycin for 4 months. Anti-inflammatory therapies included anti-IL-6R mAb (10 mg/kg) and TNF-alpha receptor fusion protein (Etanercept, 25 mg) up to day 10 (A). 3 At four months after transplantation, all recipients were conditioned with TBI (1.5 Gy Â 2 on days −6 and −5, relative to DBMT), local TI (7 Gy on day -1, relative to DBMT), and (hATG): 50 mg/kg Â 3 on days −2, −1, and 0, relative to DBMT). After DBMT, the recipients were treated with dual CB with anti-CD40 mAb (20 mg/kg, on post-DBMT days 0, 2, 5, 7, 9, and 12) and Bela (20 mg/kg, on post-DBMT days 0, 2, 5, and 15). CyA was administered for 28 days after DBMT, after which no immunosuppression was administered (A). Bela/hATG: In a previous study, the conditioning regimen consisted of low-dose TBI (1.5 Gy Â 2) on days −6 and −5 relative to simultaneous kidney and bone marrow transplantation (SKBMT), TI on day-1, hATG (50 mg/kg Â 3 on days −2, −1, and 0) and Bela (20 mg/kg Â 4 on days 0, 2, 5, and 15). A 1-month course of CyA was administered to maintain therapeutic trough levels of 250-350 ng/mL (B). 1 Bela/rATG: In the previous deceased donor study, all recipients initially underwent KTx alone with a conventional triple drug immunosuppressive regimen consisting of tacrolimus, mycophenolate mofetil, and prednisone (B). Four months after KTx alone, the recipients underwent conditioning and DBMT (delayed DBMT). The conditioning regimen for DBMT is same as the Bela/hATG regimen, except the hATG was replaced with rATG (B).
(Roche, Inc., Nutley, NJ) (200 mg/d), and prednisone (starting with 40 mg/d and tapering to a 1 mg/d maintenance dose in 2 weeks) ( Figure 1B ). Four months after KTx alone, the recipients underwent conditioning and DBMT (delayed DBMT). The conditioning regimen for DBMT was identical to the Bela/hATG regimen, with the exception of hATG, which was replaced by rATG (Thymoglobulin: Bridgewater, NJ: 10 mg/kg on day −2 and −1, relative to DBMT) ( Figure 1B ). 2 
Diabetes Induction and Management
As previously reported, 3 CIKTx recipients received streptozotocin (STZ) i.v. at a dose of 75 mg/kg (Zanosar; Teva Parenteral Medicines, Irvine, CA) 2 to 3 weeks before planned CIKTx after which blood glucose (BG) levels were monitored twice daily and measured by Accu-Check active II (Roche, Indianapolis, IN). After administration of STZ, all animals developed diabetes, defined as 3 consecutive fasting BG readings greater than 250 mg/dL with C-peptide levels less than 50 pg/mL (C-peptide, Luminex; Merck Millipore, Billerica, MA). Regular insulin (Neutral Protamine Hagedorn and Humulin R, Eli Lilly Co., Indianapolis, IN) and Lantus (Eli Lilly Co.) were administered via a sliding scale to maintain BG levels less than 200 mg/dL.
Islet Isolation and CIKTx
As previously reported, 3 the protocol for islet isolation was based on a modified human islet isolation protocol. 10 Under general anesthesia, monkeys underwent heterotopic KTx and bilateral native nephrectomies as previously described, 11 followed by islet allograft infusion into a branch of the inferior mesentery vein. The islet was gravity-infused slowly over a period of approximately 10 to 15 minutes.
Definition of Islet Rejection and BG Control After Rejection
The loss of islet function was diagnosed when the fasting BG level exceeded 250 mg/dL for 3 consecutive days. The date of graft rejection was defined as day 1 of the first 3 consecutive days of rejection. Subsequent to rejection, recipient animals were treated with exogenous insulin to maintain BG levels less than 200 mg/dL. 3 
Flow Cytometric Analyses
Peripheral blood mononuclear cells (PBMCs) were labeled with a combination of the following mAbs: CD3 (SP34-2), CD4 (L200), CD8 (SK1), CD21 (B-ly4), CD27 (M-T271), CD28 (CD28.2), CD95 (DX2), and IgM (G20-127) (BD Pharmingen, San Jose, CA), CD20 (2H7) (Biolegend, Inc., San Diego, CA) and FOXP3 (236A/E7) (eBioscience, Inc., San Diego, CA). Based on previous reports, which suggest that long-term allograft survival is associated with a predominance of immature B lymphocyte reconstitution, 
Detection of Chimerism
After standard water shock treatment, peripheral blood cells were stained with fluorescein isothiothianate-conjugated mouse antihuman HLA class I (Bw6) mAb (Miltenyi Biotec, San Diego, CA), which cross-reacts with cynomolgus monkeys. The cells were incubated for 30 minutes at 4°C, and then washed and analyzed on FACScan (Becton Dickinson, Mountain View, CA). In all experiments, the percentage of cells stained with antibody was determined using a 1-color fluorescence histogram and compared with those obtained from donor and pretreatment frozen recipient cells, which were used as positive and negative controls. The percentage of cells considered positive was determined using the fluorescence level at the beginning of the positive peak for the positive control stain as the cutoff value and by subtracting the percentage of cells stained with an isotype control. By using forward and 90°light scatter (FSC and SSC, respectively) dot plots, the lymphocyte (FSC-and SSC-low), granulocyte (SSC-high), and monocyte (FSC-high but SSC-low) populations were gated, and chimerism was determined separately for each population. Nonviable cells were excluded by propidium iodide (Thermo Fischer Scientific, Grand Island, NY) staining.
Mixed Lymphocyte Culture
T cells were purified from PBMCs by negative selection with a pan T cell isolation kit (Miltenyi Biotec). The isolated T cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) (Life Technologies, Carlsbad, CA) at a concentration of 3 μM per 10 7 cells at 37°C for 5 minutes and cultured in 96-well V-bottom plates with irradiated PBMCs or T cell activation beads (αCD2/αCD3/αCD28 mAb) (Miltenyi Biotec, San Diego, CA). After 5 days, the cells were stained with antibodies and CFSE dilution was assessed by flow cytometry.
14 Results were compared with those of previously published tolerant recipients. 14 
Detection of Donor-specific Antibody
Antidonor alloantibody was detected by flow cytometric analysis. Donor PBMCs were first incubated with recipient sera for 30 minutes at 4°C. After washing with FACS medium, fluorescein isothiothianate-conjugated mouse antihuman IgG mAb was added and incubated for 30 minutes at 4°C and then washed. After washing, PBMCs were fixed with 2% paraformaldehyde. Cells were then acquired and analyzed with a cytometer. A positive reaction was defined as a shift greater than 10 channels in mean fluorescence intensity of donor lymphocytes when using test sera compared with a pretransplant serum control.
Statistical Analyses
All measured outcomes are summarized as the mean ± standard deviation unless otherwise specified. Between-group pairwise comparison of means was performed by linear contrast in a random intercept longitudinal linear mixed effects model setting. Statistical analyses were performed with GraphPad PRISM 7.01 (GraphPad Software, Inc, San Diego, CA). We used Mantel-Cox Log-rank test to analyze the survival of different groups; P values lower than 0.05 have been considered statistically significant.
RESULTS
Nonmyeloablative Conditioning With aCD40/Bela/hATG Successfully Induced Multilineage Mixed Chimerism But Failed to Achieve Tolerance in CIKTx Four months after CIKTx, all 3 recipients were treated with the conditioning regimen, as summarized in Figure 1 , followed by DBMT. After DBMT, recipients were treated with anti-CD40 mAb and Bela and a 1-month course of CyA, before discontinuing all immunosuppression. All 3 CIKTx recipients successfully developed excellent multilineage mixed chimerism up to day 68 (Figure 2) . Nevertheless, all 3 CIKTx recipients rejected both islet and renal allografts by days 84 to 140 post-DBMT (Table 1) . Kidney allografts at autopsy showed acute T cell-mediated rejection as well as antibody-mediated rejection (AMR) with positive C4d staining in all 3 CIKTx recipients ( Figures 3A, B, and C) . Mononuclear cell infiltration was also observed in the transplanted islet ( Figure 3D ).
Conditioning With aCD40/Bela/hATG Also Failed to Induce Tolerance in KTx-Alone Recipients Despite Successful Induction of Chimerism
The failure to induce allograft tolerance despite successful induction of chimerism in 3 CIKTx recipients prompted us to examine the same conditioning regimen in KTx-alone recipients. Two cynomolgus monkey recipients underwent KTx with maintenance immunosuppression using aCD40/ rapa. Both recipients did well without rejection for 4 months ( Figure 3E ). At that point, they received the same conditioning regimen used for the CIKTx, and then underwent DBMT. Both developed excellent mixed chimerism, and in one, the chimerism was prolonged lasting up to 3 months post-DBMT (Figure 2) . The levels and duration of chimerism in all 5 recipients treated with the aCD40/Bela/hATG regimen were in fact significantly superior to those observed in the previously reported recipients that achieved long-term immunosuppression-free survival with either Bela/rATG in the delayed-DBMT 2 or Bela/hATG in the SKBMT protocol. 1 However, both KTx-alone recipients treated with the aCD40/Bela/hATG regimen rejected their renal allografts on days 116 and 127 (Table 1, Figure 3F ).
Addition of Anti-CD40 mAb Therapy Resulted in Early B-cell Sensitization
There was no significant difference in overall CD3 − CD20 + B cell reconstitution between the aCD40/Bela/hATG and Bela/rATG regimens ( Figure 4A) Figure 4B) . The memory phenotype dominant B cell subsets observed in the anti-CD40 mAb-treated recipients were consistently associated with early development of donorspecific antibody (DSA), whereas DSA was suppressed in recipients treated with the Bela/rATG regimen ( Figure 4C ). 14 In cynomolgus monkeys, peripheral blood Treg cells comprised 1% to 2% of the CD4 + T cells, but expanded to 8% ± 5.4% after donor antigen stimulation in tolerant recipients. In contrast, sustained antidonor responses were observed in both CD8 + ( Figures 5A and B) and CD4+ T cells ( Figures 5C and D) , and no donor-specific Treg cell expansion ( Figures 5E and F) was detected in any of the 5 CIKTx or KTx-alone recipients treated with the aCD40/Bela/ hATG regimen.
DISCUSSION
The CD40/CD154 pathway is pivotal to generating an effective immune response against foreign antigens. 15, 16 Blockade of this pathway with anti-CD154 mAb has been demonstrated to promote allograft tolerance in various animal models, [17] [18] [19] including our NHP model using the mixed chimerism approach. 20 However, the clinical application of this approach has been delayed because of the adverse thrombophilic effects of anti-CD154 mAb observed in NHPs 21 and humans. 22 Blocking its counterpart, CD40, with anti-CD40 mAb has therefore been tested with encouraging observations in various preclinical 23, 24 and clinical studies. 25 We also recently reported that the combination of anti-CD40 mAb and rapamycin provides effective immunosuppression without toxicity in CIKTx. 3 Because the immunosuppressive effects of anti-CD40 mAb on T MEM have been demonstrated in previous studies, 3, 4 we added anti-CD40 mAb to induce mixed chimerism in the delayed-DBMT protocol. As expected, all 3 CIKTx recipients developed excellent chimerism (Figure 2) , which was superior to that observed in recipients who achieved long-term immunosuppression-free renal allograft survival with the Bela-based regimens.
1,2 Nevertheless, none of CIKTx recipients achieved long-term allograft survival and succumbed to AMR 140 days after DBMT (Table 1) . To exclude the possibility that the exceptionally high antigenic or inflammatory properties of the islet allografts induced strong alloimmune responses, which could have triggered rejection of both islet and renal allografts, we tested the same aCD40/Bela/hATG regimen in 2 KTxalone recipients. Both KTx recipients also failed to achieve long-term immunosuppression-free renal allograft survival despite successful induction of chimerism (Table 1) . These findings rule out the notion that failure of tolerance induction with the aCD40/Bela/hATG regimen is due to the islet allograft. This was an unexpected outcome because renal allograft loss due to acute rejection is rare in recipients who successfully develop mixed chimerism with our conditioning regimen. As shown in Figure 6 and Table 1 , allograft survival was significantly shorter in the aCD40/Bela/hATG group compared to recipients in previous studies who successfully developed mixed chimerism after treatment with the Bela/hATG 1 or Bela/rATG 2 regimen. These observations have caused us to conclude that anti-CD40 mAb may inhibit the induction of allograft tolerance, at least in our mixed chimerism approach. Ramakrishnan et al 26 also reported failure of renal allograft tolerance despite induction of chimerism in recipients treated with nonmyeloablative conditioning regimen with dual CD28/ CD40 (3A8) CB. They attributed the failure of tolerance to the compartmentalized nature of the chimerism, which displayed poor lymphoid chimerism. Our studies have consistently shown that induction of donor chimerism, including the lymphoid lineage, is critical for induction of stable tolerance. 1, 20, 27 In the current study, donor chimerism was achieved; therefore, this explanation does not account for our observations.
It is far more likely that the failure of tolerance induction in the aCD40/Bela/hATG recipients was due to an inadequate regulatory response. Because the major mechanism of renal allograft tolerance via transient mixed chimerism is considered regulatory rather than deletional, 14, 28 systemic delivery of donor antigens by donor chimeric lymphoid cells may be necessary to induce antigen-specific unresponsiveness. Pilat et al 29 recently demonstrated that induction of mixed chimerism and skin allograft tolerance were not achieved by nonmyeloablative conditioning (low-dose TBI, rapamycin with anti-CD4 or anti-CD8 mAb) with CTLA4Ig when a CD40−/− mouse is used either as a recipient or a donor. Because the CD40 signal is critical for activation and maturation of the antigenpresenting cells (APCs) required for full T cell activation, 30 it is plausible that absence of CD40 signaling in either donor (direct pathway) or recipient (indirect pathway) APCs may have interfered with maturation of APCs in our NHP recipient, resulting in insufficient donor antigen presentation to the recipient regulatory cells. We hypothesize that such donor antigen presentation by donor chimeric cells is needed to induce the immunologic features of peripheral tolerance (donor-specific Treg cell expansion associated with the loss of antidonor CD8 + T-cell responses) observed in our tolerant recipients. 14 In contrast, such immunologic features, especially donor-specific Treg cell expansion, which can promote robust tolerance to the donor, 31 were not observed in those FIGURE 5 . Neither loss of antidonor CD8 + responses nor donor antigen-specific Treg cell expansion was observed in aCD40/Bela/ hATG-treated animals in vitro. CD3 + T cells isolated from aCD40/Bela/hATG-treated recipients were labeled CFSE and were cultured with irradiated self or donor PBMCs for 5 days. Cultured cells were then stained for CD4, CD8, and FOXP3. Representative flow cytometric data (A, CD8; C, CD4; E, CD4 gated FOXP3) and mean % proliferation relative to the response to self antigens (B, CD8; D, CD4; F, CD4 gated FOXP3) are shown compared with those of previously published results in 8 tolerant recipients. 14 The loss of antidonor CD8 + T-cell response was not observed in the aCD40/Bela/hATG-treated recipients, which was significantly higher than those observed in the tolerant recipients (A and B). Substantial antidonor CD4 + T-cell proliferation was observed in the aCD40/Bela/hATG-treated animals, comparable to that observed in tolerant recipients (C and D). Among these proliferated CD4 + cells after donor stimulation, a significant proportion of proliferating CD4 + cells were found in FOXP3 intolerant recipients, while such FOXP3 + cell proliferation was minimal in the aCD40/Bela/hATG-treated animals (E and F). Proliferated cells (%) = proliferated cells (%) with donor antigens − proliferated cells (%) with self antigens. Data are presented as the mean ± SD. *P < 0.05.
recipients treated with the aCD40/Bela/hATG regimen ( Figure 5 ). Although blockade of the CD154 molecule (CD40 ligand) by anti-CD154 mAb with or without donorspecific transfusion has been shown to generate donor-specific Treg cells in murine transplant models, 32, 33 blockade of its counter ligand, CD40, molecule may result in failure of Treg cell expansion and T cell tolerance. Pan et al have shown that CD40 is required for myeloid derived suppressor cell (MDSC) mediated T cell suppression and Treg cell expansion. In their murine tumor model, treatment with anti-CD40 reversed T cell tolerance and prevented tumor-associated expansion of Treg cells. 34 Similar to their observation, treatment with anti-CD40 mAb failed to induce Treg cell expansion and allograft tolerance in our NHP model.
In the current study, we observed early DSA development associated with B cell reconstitution predominantly with memory-phenotype B cells in recipients treated with aCD40/Bela/ ATG regimens (Figure 4 ). Because significant memory-type B cell predominance was not observed in the recipients treated with the Bela/ATG regimen, the enhanced B cell differentiation may have been caused by anti-CD40 mAb. Although enhancement of B-cell differentiation by the anti-CD40 mAb clone, 2C10R4, was not observed in vitro (data not shown), the agonistic effect of 2C10R4 on B cells was observed when it was used in vivo. Conversely, effective suppression of B cell differentiation by anti-CD40 mAb has been reported in NHPs. Kim et al 13 showed that additional treatment with anti-CD40 mAb (2C10R4) or Bela for 2 months consistently suppressed the DSA development in KTx recipients treated with anti-CD3 immunotoxin, tacrolimus, and alefacept in NHPs. This DSA suppression was associated with predominance of immature B cells and depressed memory B cells. Furthermore, Aoyagi et al 24 reported that long-term (6 months) treatment with anti-CD40 mAb (ASKP1240) monotherapy effectively suppressed DSA development, while 2 weeks of treatment failed to suppress DSA in their NHP KTx model. These studies may indicate that B cell differentiation is effectively inhibited as long as anti-CD40 mAb is administered. Because anti-CD40 mAb was administered only up to day 12 post-DBMT in our conditioning regimen, the short duration of the antibody administration after DBMT may have resulted in homeostatic proliferation of memory B cells which led to early DSA development.
Although anti-CD40 mAb appears to be an excellent immunosuppressive agent, it may inhibit the induction of allograft tolerance by abrogating Treg cell expansion, in addition to its other agonistic effects on B cells. Although the outcome of the current study was negative, we think it is important to document these findings for future studies on tolerance induction involving CB.
